Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $594.08 million. The enterprise value is $885.05 million.
| Market Cap | 594.08M |
| Enterprise Value | 885.05M |
Important Dates
The next confirmed earnings date is Thursday, March 5, 2026, before market open.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 66.98 million shares outstanding. The number of shares has increased by 6.27% in one year.
| Current Share Class | 66.98M |
| Shares Outstanding | 66.98M |
| Shares Change (YoY) | +6.27% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 2.60% |
| Owned by Institutions (%) | 37.99% |
| Float | 32.99M |
Valuation Ratios
The trailing PE ratio is 57.69 and the forward PE ratio is 11.76.
| PE Ratio | 57.69 |
| Forward PE | 11.76 |
| PS Ratio | 1.04 |
| Forward PS | 0.98 |
| PB Ratio | 3.53 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.96 |
| P/OCF Ratio | 10.46 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.42, with an EV/FCF ratio of 16.55.
| EV / Earnings | 87.01 |
| EV / Sales | 1.57 |
| EV / EBITDA | 13.42 |
| EV / EBIT | 18.19 |
| EV / FCF | 16.55 |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 1.65.
| Current Ratio | 1.74 |
| Quick Ratio | 1.07 |
| Debt / Equity | 1.65 |
| Debt / EBITDA | 4.81 |
| Debt / FCF | 6.38 |
| Interest Coverage | 1.61 |
Financial Efficiency
Return on equity (ROE) is 6.38% and return on invested capital (ROIC) is 8.02%.
| Return on Equity (ROE) | 6.38% |
| Return on Assets (ROA) | 4.13% |
| Return on Invested Capital (ROIC) | 8.02% |
| Return on Capital Employed (ROCE) | 9.01% |
| Weighted Average Cost of Capital (WACC) | 8.22% |
| Revenue Per Employee | $593,504 |
| Profits Per Employee | $10,707 |
| Employee Count | 950 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.95 |
Taxes
In the past 12 months, Bioventus has paid $2.16 million in taxes.
| Income Tax | 2.16M |
| Effective Tax Rate | 14.66% |
Stock Price Statistics
The stock price has decreased by -12.76% in the last 52 weeks. The beta is 0.79, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -12.76% |
| 50-Day Moving Average | 7.93 |
| 200-Day Moving Average | 7.17 |
| Relative Strength Index (RSI) | 67.33 |
| Average Volume (20 Days) | 266,494 |
Short Selling Information
The latest short interest is 1.55 million, so 2.31% of the outstanding shares have been sold short.
| Short Interest | 1.55M |
| Short Previous Month | 1.69M |
| Short % of Shares Out | 2.31% |
| Short % of Float | 4.69% |
| Short Ratio (days to cover) | 6.82 |
Income Statement
In the last 12 months, Bioventus had revenue of $563.83 million and earned $10.17 million in profits. Earnings per share was $0.15.
| Revenue | 563.83M |
| Gross Profit | 382.03M |
| Operating Income | 48.66M |
| Pretax Income | 14.73M |
| Net Income | 10.17M |
| EBITDA | 65.97M |
| EBIT | 48.66M |
| Earnings Per Share (EPS) | $0.15 |
Balance Sheet
The company has $42.16 million in cash and $341.17 million in debt, with a net cash position of -$299.00 million or -$4.46 per share.
| Cash & Cash Equivalents | 42.16M |
| Total Debt | 341.17M |
| Net Cash | -299.00M |
| Net Cash Per Share | -$4.46 |
| Equity (Book Value) | 207.26M |
| Book Value Per Share | 2.48 |
| Working Capital | 119.15M |
Cash Flow
In the last 12 months, operating cash flow was $56.03 million and capital expenditures -$2.56 million, giving a free cash flow of $53.47 million.
| Operating Cash Flow | 56.03M |
| Capital Expenditures | -2.56M |
| Free Cash Flow | 53.47M |
| FCF Per Share | $0.80 |
Margins
Gross margin is 67.76%, with operating and profit margins of 8.63% and 1.80%.
| Gross Margin | 67.76% |
| Operating Margin | 8.63% |
| Pretax Margin | 2.61% |
| Profit Margin | 1.80% |
| EBITDA Margin | 11.70% |
| EBIT Margin | 8.63% |
| FCF Margin | 9.48% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.27% |
| Shareholder Yield | -6.27% |
| Earnings Yield | 1.74% |
| FCF Yield | 9.12% |
Analyst Forecast
The average price target for Bioventus is $13.33, which is 50.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.33 |
| Price Target Difference | 50.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 6.70% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.26 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.26 |
| Piotroski F-Score | 8 |